|
|
Blood, 15 January 2008, Vol. 111, No. 2, pp. 574-582.
Prepublished online as a Blood First Edition Paper on October 16, 2007; DOI 10.1182/blood-2007-06-096370.
 Previous Article | Next Article 
Submitted June 26, 2007
Accepted October 1, 2007
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Sophie Park*, Sophie Grabar, Charikleia Kelaidi, Odile Beyne-Rauzy, Francoise Picard, Valerie Bardet, Valerie Coiteux, Genevieve Leroux, Pascale Lepelley, Marie-Therese Daniel, Stephane Cheze, Beatrice Mahe, Augustin Ferrant, Christophe Ravoet, Martine Escoffre-Barbe, Lionel Ades, Norbert Vey, Lina Aljassem, Aspasia Stamatoullas, Lionel Mannone, Herve Dombret, Keith Bourgeois, Peter Greenberg, Pierre Fenaux, and Francois Dreyfus
Service d'hematologie, Hopital Cochin, APHP, Paris, France
Departement de Statistiques, Hopital Cochin, APHP, Paris, France
Service d'hematologie, Hopital Avicenne, APHP, Bobigny, France
Service de medecine interne, Hopital Purpan, Toulouse, France
Laboratoire d'hematologie, Hopital Cochin, Paris, France
Service des maladies su Sang, Hopital Claude Huriez, CHRU Lille, Lille, France
Laboratoire d'hematologie, Hopital Avicenne, Bobigny, France
Service d'hematologie, CHRU Lille, Lille, France
Laboratoire d'hematologie, Hopital Saint-Louis, Paris, France
Service d'hematologie, CHU Caen, Caen, France
Service d'hematology, CHU Nantes, Nantes, France
Departement de Medecine Interne, Clinique Universitaires Saint-Luc, Bruxelles, Belgium
Institute Jules Bordet, Bruxelles, Belgium
Service d'hematologie, CHU Pontchaillou, Rennes, France
Departement d'Onco-Hematologie, Centre Paoli-Calmettes, Marseille, France
Service d'hematologie, CHU Chartres, Chartres, France
Service d'hematologie, CHU Rouen, Rouen, France
Service d'hematologie, CHU Nice, Nice, France
Service d'hematologie, CHU Saint-Louis, Paris, France
Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, United States
Department of Medicine, Division of Hematology, Stanford University Medical Center, Stanford, CA, United States
* Corresponding author; email: sophie.park{at}cch.aphp.fr.
We analyzed prognostic factors of response, response duration and possible impact on survival of epoetin alfa, beta or Darbepoetin alfa (DAR) +/- G-CSF in 403 MDS patients. 62% (43% major and 20% minor) and 50% erythroid responses were seen, and median response duration was 20 and 24 months according to IWG 2000 and 2006 criteria, respectively. Significantly higher response rates were observed with <10% blasts, Low and Int-1 IPSS, RBC transfusion independence, serum EPO level<200UI/l and, with IWG 2006 criteria only, shorter interval between diagnosis and treatment. Significantly longer response duration was associated with major response (IWG 2000 criteria), IPSS low-INT-1, blasts<5% and absence of multilineage dysplasia. Minor responses according to IWG 2000 were reclassified as "non responders" or "responders" according to IWG 2006 criteria. However, among those IWG 2000 minor responders, response duration did not differ between IWG 2006 "responders" and "non responders". Multivariate adjusted comparisons of survival between our cohort and the untreated MDS cohort used to design IPSS, showed similar rate of progression to AML in both cohorts, but significantly better overall survival in our cohort, suggesting that epoetin or DAR treatment may have a favourable survival impact in MDS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. A. Sekeres and D. P. Steensma
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment
Blood,
September 24, 2009;
114(13):
2575 - 2580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma
Out of this nettle, danger, we must pluck this flower, safety
Blood,
September 17, 2009;
114(12):
2364 - 2365.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Greenberg, Z. Sun, K. B. Miller, J. M. Bennett, M. S. Tallman, G. Dewald, E. Paietta, R. van der Jagt, J. Houston, M. L. Thomas, et al.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Blood,
September 17, 2009;
114(12):
2393 - 2400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood,
June 18, 2009;
113(25):
6296 - 6303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Follo, C. Finelli, C. Clissa, S. Mongiorgi, C. Bosi, G. Martinelli, M. Baccarani, L. Manzoli, A. M. Martelli, and L. Cocco
Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
J. Clin. Oncol.,
February 10, 2009;
27(5):
782 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol.,
July 20, 2008;
26(21):
3607 - 3613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg and M. Cazzola
The Role of JAK2 Mutations in RARS and Other MDS
Hematology,
January 1, 2008;
2008(1):
52 - 59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cazzola, M. G. Della Porta, and L. Malcovati
Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes
Hematology,
January 1, 2008;
2008(1):
166 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
